Latest News - Amgen
Top Corporates Hub
Amgen
Here’s What the Street is Saying About Amgen Inc. (AMGN)
19.02.2026 14:54
Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it […]
Possible Bearish Signals With Amgen Insiders Disposing Stock
19.02.2026 13:00
In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...
Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $375
19.02.2026 10:16
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $325 to $375.
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
19.02.2026 00:39
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 […]
Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit
19.02.2026 00:38
Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on several key programs during Citi’s Virtual Oncology Leadership Summit. Jean-Charles Soria, senior vice president of global development in oncology, said Amgen’s framework emphas
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $432
18.02.2026 08:27
Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $381 to $432.
Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?
14.02.2026 06:09
Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year, alongside increased net income and earnings per share. Shortly after those results, the European Commission approved UPLIZNA as an add-on therapy for certain adults with generalized myasthenia gravis, extending Amgen’s reach in rare autoimmune diseases with an infusible, twice-yearly maintenance option. We’ll now examine how the...
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
14.02.2026 03:02
InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus
Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
13.02.2026 14:57
Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and […]
Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update
13.02.2026 01:14
Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend
10.02.2026 13:15
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Amgen Inc...
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call
10.02.2026 05:37
Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO Robert Bradway highlighted that 13 products delivered double-digit sales growth and 14 surpassed $1 billion in annual sales. The company also reported continued momentum in its rare disease and oncology segments, with notable performances from its biosimilars business. Management noted that sales
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
09.02.2026 14:00
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health Corporation (CVS) Under Pressure From Medicare Proposal, Argus Holds Positive View
09.02.2026 13:26
CVS Health Corporation (NYSE:CVS) is included among 12 Unstoppable Dividend Stocks to Buy According to Analysts. On January 28, Argus trimmed its price recommendation on CVS Health Corporation (NYSE:CVS) to $90 from $91. However, the firm maintained a Buy rating on the stock. The shares fell nearly 15% after the Centers for Medicare and Medicaid […]
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?
05.02.2026 16:05
Wegovy might be getting more competition soon.
Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft
05.02.2026 15:08
AMGN hits a 52-week high on solid revenue growth and rising institutional interest, standing out against richly valued Apple and Microsoft.
Generate, an AI-driven Flagship startup, pitches an IPO
05.02.2026 11:32
The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.
Health Care Roundup: Market Talk
05.02.2026 11:13
HEALTH NEWS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0801 GMT – Siemens Healthineers has bright growth and margin potential in each of its business divisions, Jefferies analysts write in a research note.
Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains
05.02.2026 05:15
What Does Amgen's Recent Share Price Action Mean For Its Valuation? Amgen's share price can tell you a lot about what the market thinks it is worth, but the real question is whether that price still lines up with the underlying value of the business. In the last week Amgen returned 6.8%, over the past month 10.9%, year to date 11.8%, over the last year 27.0%, over three years 67.9% and over five years 81.0%. Taken together, these figures give investors a useful snapshot of how sentiment...
Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges
04.02.2026 05:03
Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.